ASX Announcement **30 July 2021**

Atomo quarterly update investor briefing

SYDNEY Australia Friday, 30 July 2021: Atomo Diagnostics Limited (ASX: AT1) (**Atomo**) is pleased to invite investors to attend an online briefing to discuss the results for the quarter ended 30 June 2021 at **11.00am (Sydney time)** on **Monday, 2 August 2021**.

During the briefing, Managing Director and CEO, John Kelly and CFO, Will Souter, will also present an activity update and discuss recent developments in relation to rapid antigen testing in Australia. This will be followed by a Q+A session.

Participants can pre-register ahead of time via the following link:
https://us02web.zoom.us/webinar/register/WN_1UG4zTOeRFmhqPrZvxFcLg

Once the registration form is completed, investors will receive a confirmation email with details on how to access the briefing. If you would like to ask a question during the briefing, please send your question ahead of the session to: george.kopsiaftis@irdepartment.com.au

For more information, please contact:

Jane Lowe
IR Department
jane.lowe@irdepartment.com.au
Phone: +61 411 117 774

John Kelly
Atomo Diagnostics
john.kelly@atomodiagnostics.com
Phone: +61 401 922 279

This announcement was authorised by John Kelly, Managing Director.

About Atomo

Atomo is an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. Atomo has supply agreements in place for tests targeting a range of infectious diseases including HIV, COVID-19, and viral vs bacterial differentiation. See more at www.atomodiagnostics.com.